Mutations in BRCA1 are often seen in BRCA1-associated breast and ovarian cancers, indicating that genetic mutations in BRCA1 are linked to loss of function in Smad3-mediated TGF-β signaling. This evidence concerns the gene SMAD3 and ovarian carcinoma.